Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Birinapant |
Synonyms | |
Therapy Description |
TL32711 (birinapant) is a a bivalent SMAC-mimetic compound, which binds to and inhibits Inhibitor of Apoptosis proteins (IAPs), leading to tumor cell death (PMID: 24563541, PMID: 26566079). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Birinapant | TL32711 | SMAC Mimetic 8 | TL32711 (birinapant) is a a bivalent SMAC-mimetic compound, which binds to and inhibits Inhibitor of Apoptosis proteins (IAPs), leading to tumor cell death (PMID: 24563541, PMID: 26566079). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | glioblastoma | predicted - sensitive | Birinapant | Preclinical - Cell culture | Actionable | In a preclinical study, TL32711 (birinapant) treatment inhibited proliferation of PTEN-deficient glioblastoma cells in culture (PMID: 32737157). | 32737157 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01940172 | Phase I | Conatumumab Birinapant | Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer | Completed | USA | 0 |
NCT03803774 | Phase I | Birinapant | Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma | Terminated | USA | 0 |